Iterum Therapeutics PLC: Iterum Therapeutics Reports First Q

--Registration Trial for uUTI Ongoing and On Track-- --Cash Runway until Mid-2024-- DUBLIN, Ireland and CHICAGO, May 12, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (Iterum), a clinical-stage

Related Keywords

Chicago , Illinois , United States , Dublin , Ireland , Corey Fishman , Judy Matthews , Nasdaq , Drug Administration , Antibacterial Resistance Leadership Group , Registration Trial , Cash Runway , Chief Executive , Trial Ongoing , Resistant Enterobacterales , Iterum Therapeutics , Qualified Infectious Disease Product , Fast Track , Exchangeable Notes , Maturity Date , Royalty Linked Notes , Private Securities Litigation Reform Act , Nasdaq Capital Market , Annual Report , Financial Officer , Consolidated Statement , Months Ended March , Gefallene Big Techs , Iterum , Herapeutics , Reports , First , Quarter , 023 , Financial , Results ,